VCYT Earnings & Financial Statements
Veracyte, Inc.
$44.69
+$1.18(+2.71%)
60
Overall
60
Value
41
Tech
81
Quality
Market Cap
$3.50B
Volume
194.14K
52W Range
$29.46 - $60.91
Target Price
$57.62
VCYT earnings and financial statements: Veracyte, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VCYT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $517.14M | $445.76M | $361.05M | $296.54M | $219.51M |
| Cost of revenue | - | $147.62M | $112.90M | $101.58M | $74.40M |
| Operating income | $57.78M | $16.14M | -$85.80M | -$41.08M | -$81.90M |
| EBITDA | $89.62M | $49.20M | -$49.42M | -$10.30M | -$61.81M |
| Net income | $66.35M | $24.14M | -$74.40M | -$36.56M | -$75.56M |
| EPS (diluted) | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.41B | $1.30B | $1.11B | $1.16B | $1.19B |
| Total liabilities | $96.44M | $124.07M | $70.80M | $81.22M | $91.31M |
| Shareholders’ equity | $1.31B | $1.18B | $1.04B | $1.08B | $1.10B |
| Cash and equivalents | $362.58M | $239.09M | $216.45M | $154.25M | $173.20M |
| Long-term debt | $35.60M | $43.24M | $7.53M | $10.65M | $14.10M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $136.31M | $75.10M | $44.22M | $7.54M | -$31.62M |
| Capital expenditure | -$9.68M | -$11.29M | -$9.96M | -$8.55M | -$5.38M |
| Free cash flow | $126.63M | $63.81M | $34.26M | -$1.01M | -$37.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VCYT | $44.69 | +2.7% | 194.14K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |